Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lomustine + thiotepa + busulfan + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Xinqiao Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The L-TBC regimen is an intensified myeloablative conditioning (MAC) protocol developed by the Hematology Medical Center at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) for patients with T-cell acute lymphoblastic leukemia (T-ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This combination therapy consists of four small molecule alkylating agents: lomustine (CCNU), thiotepa, busulfan, and cyclophosphamide. The regimen is specifically designed to address the high risk of relapse and frequent central nervous system (CNS) involvement characteristic of T-ALL. Lomustine and thiotepa are included for their superior ability to cross the blood-brain barrier, providing essential CNS prophylaxis and treatment, while busulfan and cyclophosphamide provide robust systemic anti-leukemic activity and marrow ablation. Clinical studies have demonstrated that this modified regimen can improve survival outcomes and reduce relapse rates in high-risk T-ALL populations compared to standard conditioning protocols.
- Other names
- CCNU + thiotepa + busulfan + cyclophosphamide
02
Targets
DNA
Beyond the preview
Go deeper on lomustine + thiotepa + busulfan + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lomustine + thiotepa + busulfan + cyclophosphamide.